NewAmsterdam Pharma Company N.V.

NasdaqGM:NAMS

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

💉 Vaccines

Location

Netherlands

Market Cap

USD 2.04 B

Share Price

USD 18.21

Avg Daily Volume

921,979

Change (1 day)

1.39%

Change (1 year)

1.05%

Change (YTD)

-29.14%

NewAmsterdam Pharma Company N.V. EPS (Diluted) for the Trailing 12 Months (TTM) ending March 31, 2025: USD -1.88

NewAmsterdam Pharma Company N.V. EPS (Diluted) is USD -1.88 for the Trailing 12 Months (TTM) ending March 31, 2025, a -24.50% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

NewAmsterdam Pharma Company N.V. EPS (Diluted) for the Trailing 12 Months (TTM) ending March 31, 2024 was USD -2.49, a -90.13% change year over year.
NewAmsterdam Pharma Company N.V. EPS (Diluted) for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -25.22, a 996.52% change year over year.
NewAmsterdam Pharma Company N.V. EPS (Diluted) for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -2.30.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Selling, General, and Administrative Expenses (SG&A)	Research and Development (R&D) Expenses

NasdaqGM: NAMS

NewAmsterdam Pharma Company N.V.

CEO	Dr. Michael Harvey Davidson FACC, Facp., M.D.
IPO Date	Feb. 9, 2021
Location	Netherlands
Headquarters	Gooimeer 2-35
Employees	68
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals 💉 Vaccines

Description

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.